Even though many factors have to be considered before initiating preclinical studies for MLN4924 repurposing in SPG4-HSP, our novel findings provide proof of principle that elevating spastin by inhibiting its UPP-mediated degradation has therapeutic potential for SPG4-HSP patients. Here, SPAST is linked to hereditary spastic paraplegia.